481 – 490 of 630
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Von Willebrand: The scientist, the disease, the factor, and the treatment
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Delays in maturation among adolescents with hemophilia and a history of inhibitors
(
- Contribution to journal › Article
-
Mark
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients
(
- Contribution to journal › Article
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
- 2006
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
(
- Contribution to journal › Article
-
Mark
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia
(
- Contribution to journal › Article
-
Mark
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
(
- Contribution to journal › Article